Survival analysis across three independent in vivo trials—Trial I: LN-229, Trial II: ZH-161 and Trial III: ZH-161—each with n = 6–7 tumor-bearing mice per treatment group and n = 7 treatments per trial. Doses are denoted in parentheses, and * indicates drugs used in a subset of the three trials.
